OneSource Specialty Pharma reports stellar Q3FY25 earnings with 85% EBITDA growth, setting stage for expansion
OneSource Specialty Pharma Limited, formerly Stelis Biopharma Limited, has delivered a strong financial performance in its first full quarter post-listing. The company reported Q3FY25 revenue ... Read More
OneSource secures $95m from leading investors; Strides Pharma shareholders witness surge in embedded value
OneSource Specialty Pharma Limited, previously known as Stelis Biopharma, has received equity commitments amounting to INR 8,010 million (approximately USD 95 million) from prominent institutional ... Read More